458-52-6

Basic information

• Product Name: 2-FLUORO-4-METHOXYANILINE
• Synonyms: 2-FLUORO-4-METHOXYANILINE;4-Methoxy-2-fluoroaniline hydrochloride;3-METHOXY-4-FLUOROANILINE,98+%;2-Fluoro-4-methoxyaniline, JRD;(2-fluoro-4-methoxyphenyl)amine(SALTDATA: HCl);(2-fluoro-4-methoxyphenyl)amine 1HCl;2-fluoro-4-MethoxybenzenaMine;4-Fluoro4-Methoxyaniline
• CAS NO: 458-52-6
• Molecular Formula: C₇H₈FNO
• Molecular Weight: 141.14
• Product Categories: Amines;blocks;FluoroCompounds;NULL
• Mol File: 458-52-6.mol

Chemical Properties

• Melting Point: 175°C
• Boiling Point: 203 °C at 760 mmHg
• Flash Point: 76.6 °C
• Appearance: /
• Density: 1.176g/cm³
• Vapor Pressure: 0.284mmHg at 25°C
• Refractive Index: 1.531
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 3.81±0.10(Predicted)
• CAS DataBase Reference: 2-FLUORO-4-METHOXYANILINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-FLUORO-4-METHOXYANILINE(458-52-6)
• EPA Substance Registry System: 2-FLUORO-4-METHOXYANILINE(458-52-6)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• HazardClass: 6.1
• Hazardous Substances Data: 458-52-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Fluoro-4-methoxyaniline is used as an intermediate in the synthesis of various pharmaceuticals for its unique chemical properties, contributing to the development of new drugs with specific therapeutic effects.
Used in Agrochemical Industry:
In the agrochemical sector, 2-Fluoro-4-methoxyaniline serves as a key component in the production of certain pesticides and herbicides, enhancing their effectiveness in controlling pests and weeds.
Used in Dye and Pigment Industry:
2-Fluoro-4-methoxyaniline is utilized as a building block in the creation of dyes and pigments, providing a range of colors and properties for various applications, including textiles, plastics, and printing inks.

InChI:InChI=1/C7H8FNO/c1-10-5-2-3-7(9)6(8)4-5/h2-4H,9H2,1H3

Upstream product

• 104-94-9 4-methoxy-aniline 
• 394-41-2 3-fluoro-4-nitrophenol 
• 372-20-3 3-fluorophenol 
• 394-42-3 2-fluoro-4-methoxy-benzoic acid 
• 217314-30-2 1-(2-fluoro-4-iodophenyl)-2,5-dimethyl-1H-pyrrole 
• 29632-74-4 2-fluro-4-iodoaniline 
• 367-24-8 4-bromo-2-fluoroaniline 
• 217314-31-3 1-(2-fluoro-4-methoxyphenyl)-2,5-dimethyl-1H-pyrrole 
• 209353-23-1 tert-butyl (2-fluoro-4-methoxyphenyl)carbamate 
• 446-38-8 2-fluoro-4-methoxy-1-nitro-benzene 
• 501-58-6 bis(4-methoxyphenyl)diazene 

Downstream Products

• 724788-49-2 ethyl 8-fluoro-6-(methoxy)-4-oxo-1,4-dihydro-3-quinolinecarboxylate 
• 902747-04-0 C₁₇H₁₄FN₅O₂S 
• 1402078-05-0 C₁₁H₁₂FNO₃ 
• 774232-76-7 (2,4-dichloro-pyrimidin-5-yl-methyl)-(2-fluoro-4-methoxy-phenyl)amine 
• 17302-49-7 methoxy-[1,4]benzoquinone-1-oxime 
• 39495-33-5 fluoro-[1,4]benzoquinone-1-oxime 
• 146560-55-6 7-((S)-3-Amino-pyrrolidin-1-yl)-6-fluoro-1-(2-fluoro-4-methoxy-phenyl)-5-methyl-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid ethyl ester 
• 209353-22-0 8-fluoroquinolin-6-ol 
• 628686-84-0 2-amino-N-(2-fluoro-4-methoxyphenyl)-4,6-dimethoxybenzamide 
• 458-51-5 2-fluoro-1-iodo-4-methoxybenzene 
• 501-29-1 1-chloro-2-fluoro-4-methoxybenzene 
• 458-56-0 3-fluoro-4-nitroso-anisole 

Relevant articles and documents

Quinoxaline compound, preparation method and application of quinoxaline compound in medicine

The invention provides a quinoxaline compound, a preparation method and application of the quinoxaline compound in medicine, and particularly relates to a quinoxaline compound with PAR4 antagonistic activity, a preparation method of the quinoxaline compound, a pharmaceutical composition containing the quinoxaline compound and application of the quinoxaline compound. Specifically, the invention provides a compound shown as a general formula I and/or II or a tautomer or pharmaceutically acceptable salt thereof, a preparation method of the compound, and application of the compound or the tautomer or the pharmaceutically acceptable salt in medicines for preventing and/or treating thromboembolic diseases.

Synthesis and evaluation of novel and potent protease activated receptor 4 (PAR4) antagonists based on a quinazolin-4(3H)-one scaffold

Protease activated receptor 4 (PAR4) is an important target in antiplatelet therapy to reduce the risk of heart attack and thrombotic complications in stroke. PAR4 antagonists can prevent harmful and stable thrombus growth, while retaining initial thrombus formation, by acting on the late diffusion stage of platelet aggregation, and may provide a safer alternative to other antiplatelet agents. To date, only two PAR4 antagonists, BMS-986120 and BMS-986141 have entered clinical trials for thrombosis. Thus, the development of a potent and selective PAR4 antagonist with a novel chemotype is highly desirable. In this study, we explored the activity of quinazolin-4(3H)-one-based PAR4 antagonists, beginning with their IDT analogues. By repeated structural optimisation, we developed a series of highly selective PAR4 antagonists with nanomolar potency on human platelets. Of these, 13 and 30g, with an 8-benzo[d]thiazol-2-yl-substituted quinazolin-4(3H)-one structure, showed optimal activity (h. PAR4-AP PRP IC50 = 19.6 nM and 6.59 nM, respectively) on human platelets. Furthermore, 13 and 30g showed excellent selectivity for PAR4 versus PAR1 and other receptors (IC50s > 10 μM) on human platelets. And 13 and 30g were lack of cross-reactivity for PAR1 or PAR2 (PAR1 AP FLIPR IC50 > 3162 nM, PAR2 AP FLIPR IC50 > 1000 nM) in the calcium mobilization assays. Metabolic stability assays and cytotoxicity tests of 13 and 30g indicated that these compounds could sever as promising drug candidates for the development of novel PAR4 antagonists. In summary, the quinazolin-4(3H)-one-based analogues are the first reported chemotypes with excellent activity and selectivity against PAR4, and, in the current study, we expanded the structural diversity of PAR4 antagonists. The two compounds, 13 and 30g, found in our study could be promising starting points with great potential for further research in antiplatelet therapy.

Benzotriazine compound with PAR4 antagonistic activity and application thereof

The invention discloses a benzotriazine compound with PAR4 antagonistic activity and application thereof. The present invention relates to a compound of formula (I) or a stereoisomer, tautomer, pharmaceutically acceptable salt, ester, solvate or prodrug t

Anion ligand promoted selective C-F bond reductive elimination enables C(sp2)-H fluorination

A detailed mechanism study on the anion ligand promoted selective C-H bond fluorination is reported. The role of the anion ligand has been clarified by experimental evidence and DFT calculations. Moreover, the nitrate promoted C-F bond reductive elimination enabled a selective C-H bond fluorination of various symmetric and asymmetric azobenzenes to access diverse o-fluoroanilines.

Synthesis of 2 - fluoro aniline compounds of the method

The invention discloses a method for synthesizing 2 - fluoro aniline compounds of the method, the method is: shown in formula Ia aniline compound of formula Ib α and β shown aniline compound as raw materials, through coupling reaction shown [...] azobenzene compound II, then the type II shown azobenzene compound with a palladium catalyst, fluorination reagent, additive, organic solvent, in the 30 - 150 °C temperature closed agitating the fluorination reaction, [...] compound of formula III, type III compounds are shown in the reaction under the action of a reducing [...] shown IV 2 - fluoro aniline compounds; this invention synthetic 2 - fluoro aniline compounds substrate wide adaptability, mild reaction conditions, the operation is simple, fluorinated and good selectivity, [...] aniline compounds is prepared by many drug molecule is an important intermediate and starting material, wide application prospects.

ARYL SULFONAMIDE COMPOUNDS AS CARBONIC ANHYDRASE INHIBITORS AND THEIR THERAPEUTIC USE

Disclosed herein are compounds having the following structure useful as inhibitors of carbonic anhydrase IX (CAIX) and XII, and particularly useful for reducing or eliminating metastases see Formula (I).

4,5-dihydropyrazolo [3,4-c] pyridine-2-one spiro derivatives, its preparation method and application

Disclosed are a spirocyclic derivative of 4,5-dihydropyrazolo[3,4-c]pyridine-2-one as represented by general formula (I), preparation method and use thereof, the definition of each substituent in the compound of general formula (I) being the same as the definition in the description.

PROTEIN TYROSINE KINASE MODULATORS AND METHODS OF USE

Heterocyclic pyrimidine compounds that modulate mutant-selective epidermal growth factor receptor (EGFR) and ALK kinase activity are disclosed. More specifically, the invention provides pyrimidines which inhibit, regulate and/or modulate kinase receptor, particularly in selectively modulation of various EGFR mutant activity and ALK kinase activity have been disclosed. Pharmaceutical compositions comprising the pyrimidine derivative,and methods of treatment for diseases associated with protein kinase enzymatic activity, particularly EGFR or ALK kinase activity including non-small cell lung cancer comprising administration of the pyrimidine derivative are disclosed.

5-Ureidobenzofuranone indoles as potent and efficacious inhibitors of PI3 kinase-α and mTOR for the treatment of breast cancer

A series of 5-ureidobenzofuran-3-one indoles as potent inhibitors of PI3Kα and mTOR has been developed. The best potency in cells was obtained when the urea group was extended to a 4-[2-(dimethylamino)ethyl]methylamino amidophenyl group. A 7-fluoro group

5-O-SUBSTITUTED 3-N-PHENYL-1,3,4-OXADIAZOLONES FOR MEDICAL USE

The present invention relates to compounds having a 5-O-substituted 3-N-phenyl-1,3,4-oxadiazolone structural unit which have unexpectedly high level of inhibition of FAAH (fatty acid amide hydrolase). (I)